DWA
SIOX

Douglass Winthrop Advisors’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Douglass Winthrop Advisors’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,250
Closed -$23K – 293
2018
Q2 		$23K Buy
+1,250
New +$18.4K ﹤0.01% 285

Other funds holding SIOX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Douglass Winthrop Advisors's SIOX Position: Q3 2018 in Review

Douglass Winthrop Advisors sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q3 2018, closing a stake of 1,250 shares — an estimated $23K sold.

Douglass Winthrop Advisors first reported a position in SIOX in Q2 2018 and held it in 1 quarter. The position peaked at $23K in Q2 2018. 61 funds tracked by Wall St. Rank hold SIOX as of Q3 2018.

  • Douglass Winthrop Advisors reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Douglass Winthrop Advisors sold 1,250 Sio Gene Therapies Inc. Common Stock shares in Q3 2018, an estimated $23K.
  • Douglass Winthrop Advisors first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2018 and held it in 1 quarter.
  • Douglass Winthrop Advisors's Sio Gene Therapies Inc. Common Stock position peaked at $23K in Q2 2018.
  • 61 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q3 2018.

Based on Douglass Winthrop Advisors's 13F filing for Q3 2018, filed 12 Oct 2018.